EGb761 improves cognitive function and regulates inflammatory responses in the APP/PS1 mouse.

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
• The Ginkgo biloba extract EGb761 is investigated for potential AD prevention.
• The precise mechanisms of EGb761's action in AD require further elucidation.

Purpose of the Study:

• To investigate the therapeutic effects and underlying mechanisms of EGb761 in the APP/PS1 transgenic mouse model of AD.
• To assess EGb761's impact on cognitive function, amyloid pathology, and neuroinflammation.

Main Methods:

• APP/PS1 transgenic mice were treated with EGb761 for 6 months.
• Cognitive function and amyloid plaque deposition were evaluated.
• Central inflammation markers, microglial phenotype, and neuronal protection were assessed in vivo and in vitro.

Main Results:

• EGb761 treatment improved cognitive function and reduced amyloid plaque burden in APP/PS1 mice.
• EGb761 modulated microglial activation, downregulating pro-inflammatory cytokines and upregulating anti-inflammatory markers.
• EGb761-conditioned media protected neurons from Aβ-induced damage and apoptosis.

Conclusions:

• EGb761 exerts a protective effect in the APP/PS1 mouse model of AD.
• This protection is associated with the modulation of neuroinflammation and microglial phenotype.
• EGb761 demonstrates potential as a therapeutic agent for Alzheimer's disease by regulating brain inflammation.